publication date: Jul. 5, 2019

NCI Trials

NCI Trials for July

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.


Phase II – 10250

A Phase II Study of the PARP Inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

Mayo Clinic Cancer Center LAO

Ingham, Matthew



Phase II – 10292

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors

National Cancer Institute LAO

Chen, A P

(240) 781-3320


Phase II/III – EA3161

A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA

ECOG-ACRIN Cancer Research Group

Saba, Nabil F.

(404) 778-3126


Phase III – AALL1731

A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Children’s Oncology Group

Gupta, Sumit

(416) 813-7654 X 201681


Phase III – NRG-GY019

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

NRG Oncology

Fader, Amanda Nickles

(410) 955-8240


Phase … Continue reading NCI Trials for July 2019

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.